Skip to content

Simona Pichini

19 papers in the library · 565 citations · publishing 2000-2026

Papers

Sort Most recent Most cited

Pharmacokinetic disposition in oral fluid, excretion profile, and subjective and physiological responses following oral and intranasal administration of Clophedrone (3-CMC)

October 13, 2026 Nunzia La Maida, Lourdes Poyatos, Annagiulia Di Trana et al.

Background and Purpose: Clophedrone (3-chloromethcathinone, 3-CMC) belongs to the methcathinone subclass of ring-substituted cathinones, a prominent group of new psychoactive substances (NPS) present in the illicit drug market. To date no studies have assessed concentrations and acute effects of 3-CMC in humans after self-administration. Experimental Approach: A total of 16 psychostimulant...

Acute pharmacological effects of α-PVP in humans: a naturalistic observational study.

Frontiers in Pharmacology 2025 Georgina de la Rosa, Esther Papaseit, Olga Hladun et al. 7 citations

Alpha-pyrrolidinopentiophenone (α-PVP) is a commonly consumed analogue of pyrovalerone, a synthetic cathinone with psychostimulant properties similar to those of 3,4-Methylenedioxypyrovalerone (MDPV) and cocaine. Since the pharmacology of α-PVP remains scarcely studied, we aimed to evaluate the acute pharmacological effects and its abuse potential in humans after intranasal administration. We...

DOI: 10.3389/fphar.2025.1626692 (opens in new tab) Full text (opens in new tab) Cathinones New psychoactive substances Alpha-pyrrolidinopentiophenone α-pvp α-pvp Synthetic cathinone +12

Pharmacological effects of methylone and MDMA in humans

Frontiers in Pharmacology February 17, 2023 Lourdes Poyatos, Clara Pérez‐mañá, Olga Hladun et al. 26 citations

Methylone is one of the most common synthetic cathinones popularized as a substitute for 3,4-methylenedioxymethamphetamine (MDMA, midomafetamine) owing to its similar effects among users. Both psychostimulants exhibit similar chemistry (i.e., methylone is a β-keto analog of MDMA) and mechanisms of action. Currently, the pharmacology of methylone remains scarcely explored in humans. Herein, we...

Hexahydrocannabinol Pharmacology, Toxicology, and Analysis: The First Evidence for a Recent New Psychoactive Substance.

Current Neuropharmacology 2023 Silvia Graziano, Maria Rosaria Varì, Simona Pichini et al.

During the last two years, hexahydrocannabinol (HHC), the hydrogenated derivative of tetrahydrocannabinol has been freely sold by internet websites as a "legal" replacement to THC and cannabis in a range of highly attractive branded and unbranded products, some of which are sold as "legal highs". Potentially, there could be a large demand for HHC products by individuals in Europe and...

DOI: 10.2174/1570159x21666230623104624 (opens in new tab) Full text (opens in new tab) Hexahydrocannabinol New psychoactive substances Phytocannabinoids Synthetic cannabinoids

Methylone and MDMA Pharmacokinetics Following Controlled Administration in Humans

International Journal of Molecular Sciences November 23, 2022 Lourdes Poyatos, Alfredo Fabrizio Lo Faro, Diletta Berardinelli et al. 22 citations

The aim of this study is to define, for the first time, human methylone and HMMC plasma pharmacokinetics following controlled administration of 50–200 mg methylone to 12 male volunteers. A new LC-MS/MS method was validated to quantify methylone, MDMA, and their metabolites in plasma. The study was a randomized, cross-over, double-blinded and placebo-controlled study, with a total of 468 plasma...

Ketamine: from prescription anaesthetic to New Psychoactive Substance.

Current Pharmaceutical Design May 10, 2022 M. R. Varı̀, G. Ricci, Marco Cavallo et al.

Discovered in the United States of America (USA) in the 1960s, ketamine was introduced as an anaesthetic drug to specifically replace phencyclidine. Briefly, the substance moved from the medical world to recreational users, since it was discovered that intense psychedelic experiences were obtained with dosages lower than those prescribed for anesthesia. At the end of the 90's, circulated in...

Acute Pharmacological Effects and Oral Fluid Biomarkers of the Synthetic Cannabinoid UR-144 and THC in Recreational Users

Biology March 24, 2021 Nunzia La Maida, Esther Papaseit, Lucía Martínez de Soto et al. 14 citations

Synthetic cannabinoids (SCs) are one of the most frequent classes of new psychoactive substances monitored by the EU Early Warning System and World Health Organization. UR-144 is a SC with a relative low affinity for the CB1 receptor with respect to that for the CB2 receptor. As with other cannabinoid receptor agonists, it has been monitored by the EU Early Warning System since 2012 for severe...

DOI: 10.3390/biology10040257 (opens in new tab) Cannabis Heart rate Cannabinoid receptor Blood pressure +4

Toxicology and Analysis of Psychoactive Tryptamines

International Journal of Molecular Sciences December 4, 2020 Sara Malaca, Alfredo Fabrizio Lo Faro, Alice Tamborra et al. 48 citations

Our understanding of tryptamines is poor due to the lack of data globally. Tryptamines currently are not part of typical toxicology testing regimens and their contribution to drug overdoses may be underestimated. Although their prevalence was low, it is increasing. There are few published data on the many new compounds, their mechanisms of action, onset and duration of action, toxicity, signs...

DOI: 10.3390/ijms21239279 (opens in new tab) Tryptamines Pharmacology Toxicology

Magic truffles or Philosopher's stones: a legal way to sell psilocybin?

Drug Testing and Analysis August 9, 2012 Manuela Pellegrini, Maria Concetta Rotolo, Emilia Marchei et al. 21 citations

“Magic mushrooms” is the most common name given to hallucinogenic fungi containing the psychoactive alkaloids psilocybin and psilocin. In recent years, fungis' sclerotia, commonly called “magic truffles” have become a form of supply of psychoactive Psilocybe alkaloids since Psilocybe sclerotia are not specifically included in the laws banning the sale, the purchase and the use of such...

DOI: 10.1002/dta.1400 (opens in new tab) Psilocybin Chromatography Selected reaction monitoring Solid phase extraction +3

5-HTTLPR polymorphism, mood disorders and MDMA use in a 3-year follow-up study.

Addiction Biology January 2010 Rocío Martín‐Santos, Marta Torrens, Sandra Poudevida et al.

A 3-year longitudinal prospective study was conducted to compare the incidence of substance use disorders (SUD) and non-substance use disorders (NSUD) among ecstasy users and two control groups: one of cannabis users and the other of non-drug users. The 5-HTTLPR polymorphism related to NSUD was also studied. A total of 94 subjects were included: 37 ecstasy users, 23 cannabis users and 34...

Combined immunomodulating properties of 3,4‐methylenedioxymethamphetamine (MDMA) and cannabis in humans

Addiction May 22, 2007 Roberta Pacifici, Piergiorgio Zuccaro, Magı́ Farré et al. 39 citations

ABSTRACT Aims Cell‐mediated immune function and the occurrence of mild infectious diseases was investigated. Participants Polydrug consumers of 3,4‐methylenedioxymethamphetamine (MDMA) and cannabis ( n = 37) compared to cannabis users only ( n = 23) and control group ( n = 34). Design A longitudinal prospective study with three cross‐sectional evaluations at time 0 and at 6 months and 1 year...

Disposition of Gamma-Hydroxybutyric Acid in Conventional and Nonconventional Biologic Fluids After Single Drug Administration: Issues in Methodology and Drug Monitoring

Therapeutic Drug Monitoring February 1, 2007 Sergio Abanades, Magı́ Farré, Mireia Segura et al. 66 citations

Little controlled drug administration data are available to aid in the interpretation of gamma-hydroxybutyric acid (GHB) distribution in conventional and nonconventional fluids and the potential correlation between the pharmacokinetics of GHB and drug effects. Single oral sodium GHB doses of 50 mg/kg were administered to five volunteers. Plasma, oral fluid, urine, and sweat were analyzed for...

DOI: 10.1097/ftd.0b013e3180307e5e (opens in new tab) Pharmacokinetics Pharmacology Sedative Oral administration +5

γ‐Hydroxybutyrate (GHB) in Humans

Annals of the New York Academy of Sciences August 1, 2006 Sergio Abanades, Magı́ Farré, Mireia Segura et al. 124 citations

Despite gamma-hydroxybutyrate (GHB) therapeutic uses and the increasing concern about its toxicity, few studies have addressed GHB dose-related effects under controlled administration and their relationship with its pharmacokinetics. The study design was double-blind, randomized, crossover, and controlled. As a pilot pharmacology phase I study, increasing doses of GHB were given. Single oral...

DOI: 10.1196/annals.1369.065 (opens in new tab) Gamma hydroxybutyrate Sedative Euphoriant Pharmacokinetics +4

3,4-Methylenedioxymethamphetamine (MDMA) Intoxication in an Infant Chronically Exposed to Cocaine

Therapeutic Drug Monitoring July 22, 2005 Oscar García-algar, Nuria L Pez, M. Á. Bonet et al. 39 citations

Accidental ingestion of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) was detected in an infant admitted at the Pediatric Emergency Department by drug testing in urine. Concentrations of MDMA and its principal metabolite 4-hydroxy-3-methoxymethamphetamine (HMMA) in the infant's hydrolyzed urine were 11.7 mg/L and 34.4 mg/L, respectively. Apparent febrile convulsions and cardiovascular side...

Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.

Clinical Pharmacokinetics 2005 Mireia Segura, Magí Farré, Simona Pichini et al.

3,4-Methylenedioxymethamphetamine (MDMA) is a synthetic amphetamine derivative typically used for recreational purposes. The participation of cytochrome P450 (CYP) 2D6 in the oxidative metabolism of MDMA may suggest an increased risk of acute toxicity in CYP2D6 poor metabolisers. This study was aimed at assessing the contribution of CYP2D6 to MDMA disposition in vivo using paroxetine as a...

Cell‐Mediated Immune Response in MDMA Users After Repeated Dose Administration

Annals of the New York Academy of Sciences June 1, 2002 Roberta Pacifici, Piergiorgio Zuccaro, Magı́ Farré et al. 58 citations

A bstract : Acute administration of 3,4‐methylenedioxymethamphetamine (MDMA, “ecstasy”) produces time‐dependent immune dysfunction in humans. Recreational use of MDMA generally includes repeated drug consumption, often in association with other drugs, such as alcohol and cannabis. In the laboratory setting, repeated MDMA administration to healthy MDMA consumers produced a time‐dependent immune...

DOI: 10.1111/j.1749-6632.2002.tb04183.x (opens in new tab) MDMA Immune system Pharmacology Administration probate law +1

Sweat Testing of MDMA with the Drugwipe(R) Analytical Device: A Controlled Study with Two Volunteers

Journal of Analytical Toxicology March 1, 2001 Roberta Pacifici, Magı́ Farré, Simona Pichini et al. 50 citations

Rapid on-site tests for the analysis of drugs of abuse in unconventional specimens (e.g., sweat) have recently been developed. Two healthy volunteers familiar with the effects of methylenedioxymethamphetamine (MDMA) were given 100 mg of the drug as a single oral dose. MDMA and its main metabolite 4-hydroxy-3-methoxymethamphetamine (HMMA) were determined in plasma and urine by gas...

Immunomodulating Activity of MDMA

Annals of the New York Academy of Sciences September 1, 2000 Roberta Pacifici, Piergiorgio Zuccaro, Magı́ Farré et al. 44 citations

Abstract MDMA (3,4‐methylenedioxymethamphetamine) use can cause neurochemical, behavioral and endocrine alterations, similar to those produced by exposure to acute stress, suggesting its potential as a “chemical stressor.” It is known that stressful stimuli can produce a depression of immune function and an alteration in immune cells distribution. In vitro exposure to MDMA resulted in a...

DOI: 10.1111/j.1749-6632.2000.tb05198.x (opens in new tab) MDMA Immune system Endocrinology Neurochemical +5